Corcept Therapeutics vs Supernus Pharmaceuticals
Corcept Therapeutics and Supernus Pharmaceuticals are similar in size: $761m and $719m of revenue in their latest fiscal years. Corcept Therapeutics grew faster (12.8% against 8.6%). Corcept Therapeutics kept more of each dollar of sales as profit: a net margin of 13.1% against -5.4%. Corcept Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Corcept TherapeuticsCORT, 2025 | Supernus PharmaceuticalsSUPN, 2025 |
|---|---|---|
| Revenue | $761m | $719m |
| Revenue growth | 12.8% | 8.6% |
| Net income | $99.7m | −$38.5m |
| Operating margin | 5.9% | -8.7% |
| Net margin | 13.1% | -5.4% |
| Return on equity | 15.0% | -3.7% |
| Free cash flow | $142m | $46.0m |
| Cash | $120m | $128m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $173m | — |
| Employees | 730 | 778 |
| Market value | $8.82bn | $1.65bn |
| Price vs our value range | Above our value range | Below our value range |
| Moat score | 75 (Strong) | 69 (Moderate) |
| Insider trades, 12 months | 2 buys, 111 sales | 0 buys, 20 sales |